Company Badge
USPTO Data Jan 1 1976 - Oct 13 2026
4 Patents
#411 in Cambridge, MA
#3,313 in Massachusetts
#60,641 in US
Ore Pharmaceuticals Inc.
Forward Citations = 11
15 inventors:
Cambridge, MA, United States of America
Ore Pharmaceuticals Inc.
% Expired Patents = 100.0
EPO Patents = 1
Forward Citations = 11
Loading Chart...
Loading Chart...
15 inventors (with patents filed for the assignee):
Tricia J Vos (3 out of 23 patents)
Michael E Solomon (3 out of 16 patents)
Michael A Patane (3 out of 52 patents)
4. Christopher Blackburn (2 out of 15 patents)
5. Mihaela D Danca (2 out of 2 patents)
6. Robert Coopersmith (1 out of 3 patents)
7. Christopher F Claiborne (1 out of 34 patents)
8. Thomas M Barnes (1 out of 10 patents)
9. Thomas H Marsilje, Iii (1 out of 15 patents)
10. Scott Edward Malstrom (1 out of 1 patent)
11. Dominic Picarella (1 out of 4 patents)
12. Martin P Maguire (1 out of 24 patents)
13. David W White (1 out of 18 patents)
14. Mingshi Dai (1 out of 6 patents)
15. Louis Anthony Tartaglia (1 out of 33 patents)
4 patents:
Company Overview
Ore Pharmaceuticals Inc. is a leading biopharmaceutical company focused on developing breakthrough therapies for rare and life-threatening diseases. With a dedicated team of researchers and scientists, Ore Pharma is committed to advancing novel treatments that address unmet medical needs and improve patient outcomes. Our pipeline includes promising candidates in oncology, autoimmune disorders, and genetic diseases. Visit our website to learn more about our innovative approach to drug development and our mission to make a meaningful impact on global health.
Profile summary synthesized from public USPTO records and patent filings.
IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ore Pharmaceuticals Inc.. Retrieved from https://idiyas.com/company/ore-pharmaceuticals
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
1 patent (EPO):
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]